Protein aggregation inhibitor

An amphoteric polymer compound derived from ε-poly-L-lysine and succinic anhydride addresses protein aggregation issues in protein drugs by providing effective inhibition and enzyme protection at low concentrations, enhancing stability during storage and purification.

WO2024232422A1PCT designated stage expired Publication Date: 2024-11-14JAPAN ADVANCED INST OF SCI & TECH
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017318
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing protein drugs, particularly antibody drugs and enzyme preparations, face stability issues during long-term storage and purification due to protein aggregation, requiring high concentrations of inhibitors like trehalose, polyethylene glycol, and arginine to effectively suppress aggregation.

Method used

An amphoteric polymer compound represented by a specific formula, derived from ε-poly-L-lysine and succinic anhydride, is used to inhibit protein aggregation effectively at low concentrations, providing protection against denaturation and maintaining enzyme activity.

Benefits of technology

The amphoteric polymer compound effectively inhibits protein aggregation and protects enzyme activity at lower concentrations than conventional methods, ensuring stability during storage and purification processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024017318_14112024_PF_FP_ABST
    Figure JP2024017318_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a novel protein aggregation inhibitor capable of exhibiting a protein aggregation inhibitory effect even when added at a low concentration, by means of an amphoteric polymer compound represented by formula I.
Need to check novelty before this filing date? Find Prior Art

Description

Protein aggregation inhibitors

[0001] The present invention relates to a protein aggregation inhibitor.

[0002] In recent years, expectations for protein pharmaceuticals, including antibody drugs and enzyme preparations, have been rising. A major issue in the development and practical application of protein pharmaceuticals, particularly antibody drugs and enzyme preparations, is stability. Stability issues can be broadly categorized into two types: inactivation during long-term storage and aggregation during purification. Inactivation during long-term storage often manifests as aggregation due to freezing. Therefore, the stability issue can be understood as the prevention of protein aggregation, both during long-term storage and during purification.

[0003] Trehalose (Non-Patent Document 1), polyethylene glycol (Non-Patent Document 2), arginine (Non-Patent Document 3), and polysulfobetaine (Non-Patent Document 4, Non-Patent Document 5, Patent Document 1, Patent Document 2) have been reported as compounds effective in inhibiting protein aggregation.

[0004] International Publication No. WO2018 / 003909 International Publication No. WO2017 / 209121

[0005] Tomita S., Nagasaki Y., Shiraki K., Biotechnol Bioengineer., 2012, 109, 2543-2552.Zhao X., et al., PNAS, 2006, 103, 17707-17712.Muraoka T., Adachi K., et al., Angenwangte Chem. Int. Ed., 2013, 125, 2490-2494.Rajan R, Matsumura K., J. Mater. Chem. B, 2015,3, 5683-5689.Debas A, et al., Mol. Syst. Des. Eng. 2022, 7, 1327-1335.

[0006] According to the investigations of the present inventors, the compounds having a protein aggregation inhibitory effect disclosed in Non-Patent Documents 1 to 5 and Patent Documents 1 and 2 have the disadvantage that they need to be added at high concentrations in order to exert a sufficient protein protection effect.

[0007] It would be highly desirable if there were a compound that could exert a protein aggregation inhibitory effect when added at a low concentration.

[0008] Therefore, an object of the present invention is to provide a novel protein aggregation inhibitor that can exhibit a protein aggregation inhibitory effect even when added at a low concentration.

[0009] The present inventors have conducted extensive research into protein aggregation inhibitors and have discovered that the above-mentioned object can be achieved by the protein aggregation inhibitor described below, thereby arriving at the present invention.

[0010] Therefore, the present invention includes the following (1): (1) An amphoteric polymeric compound represented by the following formula I: Formula I: (In Formula I, x, y, and z are integers indicating the number of repeating units dispersed throughout the molecule, x is an integer ranging from 3 to 17, y is an integer ranging from 12 to 29, z is an integer ranging from 1 to 4, and L 1 is a divalent substituent represented by the following formula La or Lb: (However, in formula La, R21 and R22 are each independently any group selected from a hydrogen atom and a saturated or unsaturated C4 to C14 hydrocarbon group (excluding the case where R21 and R22 are both hydrogen atoms), or R21 and R22 together form a saturated or unsaturated five- or six-membered ring hydrocarbon group.) Formula Lb: (In formula Lb, R31, R32, R33 and R34 are each independently any group selected from a hydrogen atom and a saturated or unsaturated C4 to C14 hydrocarbon group (excluding the case where R31, R32, R33 and R34 are all simultaneously hydrogen atoms), or R31, R32, R33 and R34 are: R32 and R33 together form a saturated or unsaturated five- or six-membered hydrocarbon group, and R31 and R34 are hydrogen atoms, or R31, R32, R33 and R34 are: R31 and R32 together form a saturated or unsaturated five- or six-membered hydrocarbon group, and R33 and R34 are hydrogen atoms, or R31, R32, R33 and R34 are: R33 and R34 together form a saturated or unsaturated five- or six-membered hydrocarbon group, and R31 and R32 are hydrogen atoms. 1 The repeating unit containing L 1 is a divalent substituent represented by formula La, the divalent substituents are contained in the molecule at an average number z of the number contained in the molecule, including the case where the end closer to R21 in formula La is bonded to the side closer to the PLL chain in formula I, and the case where the end closer to R22 in formula La is bonded to the side closer to the PLL chain in formula I, 1 The repeating unit containing L 1 is a divalent substituent represented by formula Lb, the divalent substituents are contained in the molecule at an average number z of the number contained in the molecule, including the case where the end closer to R31 in formula Lb is bonded to the side closer to the PLL chain in formula I, and the case where the end closer to R34 in formula Lb is bonded to the side closer to the PLL chain in formula I, 2 is -CH 2 -CH 2 - group, or -CH 2 -CH 2 -CH 2 A divalent substituent represented by a - group, 2 The repeating unit containing L 2 is a divalent substituent represented by -CH 2 -CH 2- group, and -CH 2 -CH 2 -CH 2 The average number of substituents contained in the molecule is y, including cases where the substituents are divalent substituents represented by a - group.

[0011] (2) ε-poly-L-lysine is reacted with succinic anhydride and a compound represented by the following formula II: (However, in Formula II, L 1 is a divalent substituent represented by formula La or formula Lb described in (1).

[0012] (3) The amphoteric polymer compound according to (1), which is an amphoteric polymer compound represented by the following formula Ia: Formula Ia: (wherein in formula Ia, x, y, z have the same numerical values ​​as described for formula I in (1), and L 1 is a divalent substituent as described for formula I in (1).

[0013] (4) The amphoteric polymer compound according to (1), wherein the value of x+y+z is an integer in the range of 23 to 39.

[0014] (5) The saturated or unsaturated C4 to C14 hydrocarbon group is -C n H 2n+1 group (where n is an integer of 4 to 14), -C n H 2n-1 group (where n is an integer of 4 to 14), -C n H 2n-3 group (where n is an integer of 4 to 14), -C n H 2n-5 (1) The amphoteric polymer compound according to (1), wherein n is any group selected from the group consisting of:

[0015] (6) A protein aggregation inhibitor comprising the amphoteric polymer compound according to any one of (1) to (5).

[0016] (7) A composition for inhibiting protein aggregation, comprising the amphoteric polymer compound according to any one of (1) to (5).

[0017] (8) An agent for protecting enzyme activity, comprising the amphoteric polymer compound according to any one of (1) to (5).

[0018] (9) A composition for protecting enzyme activity, comprising the amphoteric polymer compound according to any one of (1) to (5).

[0019] (10) Use of the amphoteric polymer compound according to any one of (1) to (5) for inhibiting protein aggregation.

[0020] (11) Use of the amphoteric polymer compound according to any one of (1) to (5) for protecting enzyme activity.

[0021] (12) A method for inhibiting protein aggregation, comprising a step of adding the amphoteric polymer compound according to any one of (1) to (5) to a solution or dispersion of a protein to be protected, prior to dissolving or dispersing the protein to be protected, or after dissolving or dispersing the protein to be protected.

[0022] (13) A method for producing a protein solution or dispersion in which aggregation is inhibited by the method for inhibiting protein aggregation according to (12).

[0023] (14) A method for protecting the enzymatic activity of an enzyme protein, comprising the step of adding the amphoteric polymer compound according to any one of (1) to (5) to a solution or dispersion of the enzyme protein to be protected, either prior to dissolving or dispersing the enzyme protein to be protected, or after dissolving or dispersing the enzyme protein to be protected.

[0024] (15) A method for producing an enzyme protein solution or dispersion whose enzymatic activity is protected by the method for protecting the enzymatic activity of an enzyme protein according to (14).

[0025] The present invention provides a novel protein aggregation inhibitor, which can exert its effect even when added at a low concentration.

[0026] FIG. 1A is an explanatory diagram of the synthesis flow from PLL to PLL-SA. FIG. 1B is an explanatory diagram of the synthesis flow from PLL-SA to PLL-SA-DDSA. FIG. 2A shows the structure of PLL-SA. FIG. 2B shows 1D measured by H-NMR 2 Figure 2C shows the structure of PLL-SA-DDSA. Figure 2D shows the structure of PLL-SA-DDSA. 1 D measured by H-NMR 2 Figure 2E shows the spectrum of PLL-SA(65)-DDSA(2) in O. 1 D measured by H-NMR 2 Figure 2F shows the spectrum of PLL-SA(65)-DDSA(5) in O. 1 D measured by H-NMR 2 Figure 2G shows the spectrum of PLL-SA(65)-DDSA(8) in O. 1 D measured by H-NMR 2Figure 3 shows the spectrum of PLL-SA(65)-DDSA(10) in 0. Figure 3 is a graph showing the change in absorbance when lysozyme, lysozyme with PLL-SA(65), and lysozyme with PLL-SA(65)-DDSA(8) were heated for up to 1 hour. Figure 4A shows the graph of the residual enzyme activity measured after adding PLL-SA, PLL-SA-DDSA2, PLL-SA-DDSA5, PLL-SA-DDSA8, or PLL-SA-DDSA10 to lysozyme at 2.5 mg / mL and heating at 90°C for 30 minutes, with the unheated value set to 100%. 4B is a graph showing the results of measuring the residual enzyme activity after adding PLL-SA, PLL-SA-DDSA2, PLL-SA-DDSA5, PLL-SA-DDSA8, or PLL-SA-DDSA10 to lysozyme at 5 mg / mL and heat-treating at 90°C for 30 minutes, with the unheated value set to 100%. 4C is a graph showing the results of measuring the residual enzyme activity after adding PLL-SA, PLL-SA-DDSA2, PLL-SA-DDSA5, PLL-SA-DDSA8, or PLL-SA-DDSA10 to lysozyme at 7.5 mg / mL and heat-treating at 90°C for 30 minutes, with the unheated value set to 100%. 4D is a graph showing the results of adding PLL-SA, PLL-SA-DDSA2, PLL-SA-DDSA5, PLL-SA-DDSA8, or PLL-SA-DDSA10 to lysozyme at 10 mg / mL, heat-treating at 90°C for 30 minutes, and then measuring the residual enzyme activity, with the unheated value set to 100%. Fig. 5 is a graph showing the results of adding PLL-SA-OSA8, PLL-SA-DSA8, PLL-SA-CPDA8, or PLL-SA-PA8 to lysozyme, heat-treating at 90°C for 30 minutes, and then measuring the residual enzyme activity, with the unheated value set to 100%. FIG. 6 is a graph showing the results of adding PLL-SA, PLL-SA-DDSA2, PLL-SA-DDSA5, PLL-SA-DDSA8, or PLL-SA-DDSA10 to LDH (lactate dehydrogenase) at concentrations of 0.05 mg / mL, 0.075 mg / mL, 0.1 mg / mL, 0.25 mg / mL, 0.5 mg / mL, or 1 mg / mL, and then heat-treating the mixture at 90°C for 30 minutes, followed by measuring the residual enzyme activity, with the unheated value set as 100%.FIG. 7 is a graph showing the results of measuring the residual enzyme activity after adding PLL-SA30-DDSA8, PLL-SA50-DDSA8, PLL-SA65-DDSA8, or PLL-SA70-DDSA8 to lysozyme and heat-treating at 90°C for 30 minutes, with the unheated value set as 100%.

[0027] The present invention will be described in detail below with reference to specific embodiments, but the present invention is not limited to the specific embodiments described below.

[0028] [Amphoteric Polymer Compound of the Present Invention] The present invention resides in an amphoteric polymer compound represented by the following formula I.

[0029] Formula I:

[0030] [x, y, z] In Formula I, x, y, and z are integers indicating the number of each repeating unit dispersed throughout the molecule. For the sake of the representation of Formula I, the repeating units are collectively described by type. However, as those skilled in the art of polymers will understand, in actual molecules, the repeating units are not consecutively present within the molecule, but are irregularly modified within the molecule by modification reactions, resulting in irregularly present repeating units. Therefore, x, y, and z indicate the total number of repeating units present.

[0031] The amphoteric polymer compound of the present invention is a polymer compound that can be prepared by modifying the repeating units of the starting material ε-poly-L-lysine with an acid anhydride. Therefore, the number n of repeating units contained in the starting material ε-poly-L-lysine satisfies the relationship n=x+y+z with respect to x, y, and z.

[0032] In a preferred embodiment, the ε-poly-L-lysine used may be ε-poly-L-lysine produced by microbial fermentation. In a preferred embodiment, the ε-poly-L-lysine derived from the microorganism has extremely high uniformity in molecular length, i.e., the number n of repeating units contained in the molecule.

[0033] In a preferred embodiment, the number of repeating units contained, n, can be, for example, an integer in the range of 23 to 39, an integer in the range of 23 to 37, or an integer in the range of 23 to 35, or an integer in the range of 25 to 39, an integer in the range of 25 to 37, or an integer in the range of 25 to 35, or an integer in the range of 26 to 35, an integer in the range of 27 to 35, an integer in the range of 28 to 35, an integer in the range of 29 to 35, or an integer in the range of 30 to 35, or an integer in the range of 27 to 34, an integer in the range of 28 to 34, an integer in the range of 29 to 34, or an integer in the range of 30 to 34, or an integer in the range of 27 to 33, an integer in the range of 28 to 33, an integer in the range of 29 to 33, an integer in the range of 30 to 33, or an integer in the range of 31 to 33. A particularly preferred value of n is 32.

[0034] In preferred embodiments, x can be, for example, an integer ranging from 3 to 17, preferably from 4 to 16, preferably from 5 to 15, preferably from 6 to 14. Alternatively, x can be, for example, an integer ranging from 5 to 16, from 5 to 12, from 5 to 10, or from 5 to 9. Alternatively, x can be, for example, an integer ranging from 6 to 16, from 6 to 12, from 6 to 10, or from 6 to 9. Alternatively, x can be, for example, an integer ranging from 7 to 16, from 7 to 12, from 7 to 10, or from 7 to 9.

[0035] In preferred embodiments, y can be, for example, an integer in the range of 12 to 29, preferably 13 to 28, preferably 14 to 27, preferably 15 to 26. Alternatively, y can be, for example, an integer in the range of 11 to 28, 11 to 26, or 11 to 20. Alternatively, y can be, for example, an integer in the range of 14 to 28, 14 to 26, or 14 to 20. Alternatively, y can be, for example, an integer in the range of 16 to 28, 16 to 26, or 16 to 20.

[0036] In a preferred embodiment, z can be an integer ranging from, for example, 1 to 5, preferably from 1 to 4. Alternatively, z can be an integer ranging from, for example, 1 to 3, or 1 to 2.

[0037] In the examples described below, for example, PLLSA65DDSA8 is described. This PLLSA65DDSA8 can also be expressed as PLL-SA65-DDSA8, and indicates that the ratio of the content of each modified repeating unit in the corresponding molecular population in terms of moles is PLL:SA:DDSA = 27:65:8. When expressed as the ratio of x, y, and z, this can be expressed as x:y:z = 27:65:8.

[0038] For example, when the modification to an ε-poly-L-lysine molecule where n=32 is calculated from this ratio value of PLL-SA65-DDSA8, x is calculated to be 8.64, y is 20.8, and z is 2.56. Therefore, by rounding up or down the decimal points of each value, it is possible to calculate, as an example of a representative molecule, a molecule where x+y+z=32, where x is 8 or 9, and y is 20 or 21; or a molecule where x+y+z=32, where x is 8 or 9, and z is 2 or 3; or a molecule where x+y+z=32, where y is 20 or 21, and z is 2 or 3.

[0039] Similarly, from the ratio value of PLL-SA65-DDSA8, for example, as an example of a representative molecule modified with an ε-poly-L-lysine molecule with n=39, where x is 10.53, y is 25.35, and z is 3.12, a molecule in which x+y+z=39, x is 10 or 11, and y is 25 or 26, can be calculated; alternatively, a molecule in which x+y+z=39, x is 10 or 11, and z is 3 or 4, can be calculated; or alternatively, a molecule in which x+y+z=39, y is 25 or 26, and z is 3 or 4 can be calculated.

[0040] Similarly, from the ratio value of PLL-SA65-DDSA8, for example, as an example of a representative molecule modified with an ε-poly-L-lysine molecule with n=23, where x is 6.21, y is 14.95, and z is 1.84, a molecule in which x+y+z=23, x is 6 or 7, and y is 14 or 15, can be calculated; alternatively, a molecule in which x+y+z=23, x is 6 or 7, and z is 1 or 2, can be calculated; or alternatively, a molecule in which x+y+z=23, y is 14 or 15, and z is 1 or 2 can be calculated.

[0041] When performing such calculations, in order to determine combinations of integer values ​​of x, y, and z for representative molecules of the amphoteric polymer compounds of the present invention described in the Examples below, the calculated values ​​of x, y, and z derived from the value of n and the value of the modification ratio for each molecule are listed in the following table.

[0042] The calculated values ​​of x, y, and z for PLL-SA65-DDSA8 are shown in Table 1-1.

[0043]

[0044] For example, for n = 23 in Table 1-1, any two of the calculated values ​​of x, y, and z are selected and rounded up or down to obtain a combination of integer values, and the remaining integer value is calculated from the formula x + y + z = 23, thereby obtaining a combination of integer values ​​of x, y, and z that is a representative molecule derived from the values ​​of the modification ratios of each molecule, as described above.

[0045] That is, for example, when n = 23, the calculated values ​​are x 6.21, y 14.95, and z 1.84, so a molecule where x + y + z = 23, where x is an integer value of 6 or 7 and y is 14 or 15, can be calculated as a representative molecule; alternatively, a molecule where x + y + z = 23, where x is an integer value of 6 or 7 and z is 1 or 2, can be calculated as a representative molecule; alternatively, a molecule where x + y + z = 23, where y is an integer value of 14 or 15 and z is 1 or 2 can be calculated as a representative molecule.

[0046] In this way, a representative combination of integer values ​​of x, y, and z for the numerator can be determined from the calculated values ​​(real values) of x, y, and z corresponding to each n for PLL-SA65-DDSA8 shown in Table 1-1.

[0047] The calculated values ​​of x, y, and z for PLL-SA65-DDSA10 are shown in Table 1-2. Using this Table 1-2 in the same way as Table 1-1 above, it is possible to find a representative combination of integer values ​​of x, y, and z for the numerator from the calculated values ​​(real values) of x, y, and z corresponding to each n for PLL-SA65-DDSA10.

[0048]

[0049] The calculated values ​​of x, y, and z for PLL-SA65-DDSA5 are shown in Table 1-3. Using this Table 1-3 in the same way as Table 1-1 above, it is possible to find a representative combination of integer values ​​of x, y, and z for the numerator from the calculated values ​​(real values) of x, y, and z corresponding to each n for PLL-SA65-DDSA5.

[0050]

[0051] The calculated values ​​of x, y, and z for PLL-SA50-DDSA8 are shown in Table 1-4. Using this Table 1-4 in the same way as Table 1-1 above, it is possible to find a representative combination of integer values ​​of x, y, and z for the numerator from the calculated values ​​(real values) of x, y, and z corresponding to each n for PLL-SA50-DDSA8.

[0052]

[0053] The calculated values ​​of x, y, and z for PLL-SA70-DDSA8 are shown in Table 1-5. Using this Table 1-5 in the same way as Table 1-1 above, it is possible to find a representative combination of integer values ​​of x, y, and z for the numerator from the calculated values ​​(real values) of x, y, and z corresponding to each n for PLL-SA70-DDSA8.

[0054]

[0055] [Formula L 1 In formula I, L 1is a divalent substituent represented by formula La or formula Lb described below.

[0056] [Divalent Substituent Represented by Formula La] Formula La:

[0057] In formula La, R21 and R22 can each independently represent, for example, any group selected from a hydrogen atom and a saturated or unsaturated C4 to C14 hydrocarbon group.

[0058] In a preferred embodiment, the saturated or unsaturated C4 to C14 hydrocarbon group can be a straight-chain or branched, cyclic or acyclic hydrocarbon group, for example, -C n H 2n+1 group (where n is an integer of 4 to 14), -C n H 2n-1 group (where n is an integer of 4 to 14), -C n H 2n-3 group (where n is an integer of 4 to 14), -C n H 2n-5 groups (where n is an integer of 4 to 14). In a preferred embodiment, n can be an integer ranging from 4 to 14, 5 to 14, 6 to 14, 7 to 14, 8 to 14, 9 to 14, or 10 to 14. Alternatively, n can be an integer ranging from 4 to 13, 5 to 13, 6 to 13, 7 to 13, 8 to 13, 9 to 13, or 10 to 13. Alternatively, n can be an integer ranging from 4 to 12, 5 to 12, 6 to 12, 7 to 12, 8 to 12, 9 to 12, or 10 to 12. In a preferred embodiment, examples of the linear or branched, saturated or unsaturated hydrocarbon group include linear -C n H 2n+1 groups (where n is an integer within the above range).

[0059] However, in formula La, the case where R21 and R22 are simultaneously hydrogen atoms is not included.

[0060] Alternatively, in formula La, R21 and R22, together with the carbon atom to which R21 is bonded and the carbon atom to which R22 is bonded, can form a saturated or unsaturated five- or six-membered ring hydrocarbon group. Examples of five-membered ring hydrocarbon structures include cyclopentane, cyclopentene, and cyclopentadiene. Examples of six-membered ring hydrocarbon structures include cyclohexane, cyclohexene, cyclohexadiene, and benzene.

[0061] [Divalent Substituent Represented by Formula Lb] Formula Lb:

[0062] In formula Lb, R31, R32, R33, and R34 can each independently represent, for example, any group selected from a hydrogen atom and a saturated or unsaturated C4 to C14 hydrocarbon group.

[0063] In a preferred embodiment, the saturated or unsaturated C4 to C14 hydrocarbon group may be a linear or branched, cyclic or acyclic hydrocarbon group, and may be any of the saturated or unsaturated C4 to C14 hydrocarbon groups described above for R21 and R22.

[0064] However, in formula Lb, the case where all of R31, R32, R33 and R34 are simultaneously hydrogen atoms is not included.

[0065] Alternatively, in formula Lb, R31, R32, R33, and R34 can be such that R32 and R33, together with the carbon atom to which R32 is bonded and the carbon atom to which R33 is bonded, form a saturated or unsaturated five- or six-membered ring hydrocarbon group, and R31 and R34 are hydrogen atoms. Examples of five-membered ring hydrocarbon structures include cyclopentane, cyclopentene, and cyclopentadiene. Examples of six-membered ring hydrocarbon structures include cyclohexane, cyclohexene, cyclohexadiene, and benzene.

[0066] Alternatively, in formula Lb, R31, R32, R33, and R34 can be such that R31 and R32, together with the carbon atom to which R31 is bonded and the carbon atom to which R32 is bonded, form a saturated or unsaturated five- or six-membered ring hydrocarbon group, and R33 and R34 are hydrogen atoms. Examples of the five-membered ring hydrocarbon structure and the six-membered ring hydrocarbon structure include the structures described above.

[0067] Alternatively, in formula Lb, R31, R32, R33, and R34 can be such that R33 and R34, together with the carbon atom to which R33 is bonded and the carbon atom to which R34 is bonded, form a saturated or unsaturated five- or six-membered ring hydrocarbon group, and R31 and R32 are hydrogen atoms. Examples of the five-membered ring hydrocarbon structure and the six-membered ring hydrocarbon structure include the structures described above.

[0068] [L 1 Repeating units containing] L 1 The repeating unit containing L 1 is a divalent substituent represented by formula La, the divalent substituents are contained in the molecule with an average number z of substituents contained in the molecule, including the case where the end closer to R21 in formula La is bonded to the side closer to the PLL chain in formula I, and the case where the end closer to R22 in formula La is bonded to the side closer to the PLL chain in formula I.

[0069] L 1 The repeating unit containing L 1 is a divalent substituent represented by formula Lb, the divalent substituents are contained in the molecule with an average number z of substituents contained in the molecule, including the case where the end closer to R31 in formula Lb is bonded to the side closer to the PLL chain in formula I, and the case where the end closer to R34 in formula Lb is bonded to the side closer to the PLL chain in formula I.

[0070] [L 2 a divalent substituent represented by the formula: L 2 is -CH 2 -CH 2 - group, or -CH 2 -CH 2 -CH2 - group, and preferably -CH 2 -CH 2 - group.

[0071] [L 2 Repeating units containing] L 2 The repeating unit containing L 2 is a divalent substituent represented by -CH 2 -CH 2 - group, and -CH 2 -CH 2 -CH 2 The number of divalent substituents contained in the molecule is y, including cases where the divalent substituents are divalent groups represented by a - group.

[0072] [Amphoteric polymer compound represented by formula Ia] In formula I, L 2 is preferably —CH 2 -CH 2 In this case, the amphoteric polymer compound of formula I becomes an amphoteric polymer compound represented by the following formula Ia.

[0073] Formula Ia:

[0074] In formula Ia, x, y, and z are the values ​​as described for formula I in claim 1.

[0075] In formula Ia, L 1 is a divalent substituent as described for Formula I.

[0076] [Production of the Amphoteric Polymer Compound of the Present Invention] The amphoteric polymer compound of the present invention can be obtained by reacting ε-poly-L-lysine with succinic anhydride and a compound represented by the following formula II.

[0077] [ε-Poly-L-lysine]

[0078] [Succinic anhydride]

[0079] Compound of Formula II:

[0080] In Formula II, L1 is a divalent substituent of formula La or Lb as described above in formula I.

[0081] The compound of formula II is L 1 is a divalent substituent of formula La as described above in formula I, the compound is of formula IIa:

[0082] Formula IIa:

[0083] In formula IIa, R21 and R22 can be the groups described above in formula La of formula I.

[0084] The compound of formula II is L 1 is a divalent substituent of formula Lb as described above in formula I, the compound is of formula IIb:

[0085] Formula IIb:

[0086] In Formula IIb, R31, R32, R33 and R34 can be the groups described above in Formula Lb of Formula I.

[0087] [Protein Aggregation Inhibition] The amphoteric polymer compound of the present invention can exhibit an excellent protein aggregation inhibitory effect on the protein to be protected by adding it to a solution or dispersion of the protein to be protected prior to dissolving or dispersing the protein to be protected or after dissolving or dispersing the protein to be protected.

[0088] Therefore, the present invention also relates to a protein aggregation inhibitor comprising the above-mentioned amphoteric polymer compound. The present invention also relates to a protein aggregation inhibitor composition comprising the above-mentioned amphoteric polymer compound. The present invention also relates to use of the above-mentioned amphoteric polymer compound for inhibiting protein aggregation.

[0089] Furthermore, the present invention also relates to a method for inhibiting protein aggregation, which comprises a step of adding the above-mentioned amphoteric polymer compound to a solution or dispersion of a protein to be protected, either prior to dissolving or dispersing the protein to be protected, or after dissolving or dispersing the protein to be protected.

[0090] Furthermore, the present invention also relates to a method for producing an aggregation-inhibited protein solution or dispersion obtained by such a method for inhibiting protein aggregation.

[0091] In a preferred embodiment, the amphoteric polymer compound of the present invention can be contained in a solution or dispersion of a protein to be protected in order to inhibit protein aggregation.

[0092] The content of the amphoteric polymer compound of the present invention in the solution is, for example, in the range of 0.02 to 25, 0.03 to 25, 0.04 to 25, 0.05 to 25, 0.06 to 25, 0.07 to 25, 0.08 to 25, 0.09 to 25, or 0.1 to 25 mg / mL, or 0.02 to 20, 0.03 to 20, 0.04 to 20, 0.05 to 20, 0.06 to 20, 0.07 to 20, 0.08 to 20, 0.09 to 20, or 0.1 to 20 mg / mL. mL, or 0.02 to 15, 0.03 to 15, 0.04 to 15, 0.05 to 15, 0.06 to 15, 0.07 to 15, 0.08 to 15, 0.09 to 15, 0.1 to 15 mg / mL, or 0.02 to 10, 0.03 to 10, 0.04 to 10, 0.05 to 10, 0.06 to 10, 0.07 to 10, 0.08 to 10, 0.09 to 10, 0.1 to 10 mg / mL.

[0093] Alternatively, the content of the amphoteric polymer compound of the present invention in the solution may be, for example, in the range of 0.2 to 25, 0.5 to 25, 0.7 to 25, 1.0 to 25, 1.5 to 25, 1.8 to 25, 2.0 to 25, 2.4 to 25, 2.5 to 25, or 3.0 to 25 mg / mL, or 0.2 to 20, 0.5 to 20, 0.7 to 20, 1.0 to 20, 1.5 to 20, 1.8 to 20, 2.0 to 20, 2.4 to 20, 2.5 to 20, or 3.0 to 20 mg / mL. mg / mL, or alternatively, 0.2 to 15, 0.5 to 15, 0.7 to 15, 1.0 to 15, 1.5 to 15, 1.8 to 15, 2.0 to 15, 2.4 to 15, 2.5 to 15, or 3.0 to 15 mg / mL, or alternatively, 0.2 to 10, 0.5 to 10, 0.7 to 10, 1.0 to 10, 1.5 to 10, 1.8 to 10, 2.0 to 10, 2.4 to 10, 2.5 to 10, or 3.0 to 10 mg / mL.

[0094] Alternatively, the content of the amphoteric polymer compound of the present invention in the solution is, for example, in the range of 0.02 to 7.5, 0.03 to 7.5, 0.04 to 7.5, 0.05 to 7.5, 0.06 to 7.5, 0.07 to 7.5, 0.08 to 7.5, 0.09 to 7.5, or 0.1 to 7.5 mg / mL, or 0.02 to 5, 0.03 to 5, 0.04 to 5, 0.0 The concentration can be in the range of 0.5 to 5, 0.06 to 5, 0.07 to 5, 0.08 to 5, 0.09 to 5, or 0.1 to 5 mg / mL, or in the range of 0.02 to 2.5, 0.03 to 2.5, 0.04 to 2.5, 0.05 to 2.5, 0.06 to 2.5, 0.07 to 2.5, 0.08 to 2.5, 0.09 to 2.5, or 0.1 to 2.5 mg / mL.

[0095] Alternatively, the content of the amphoteric polymer compound of the present invention in the solution may be, for example, in the range of 0.02 to 2.0, 0.03 to 2.0, 0.04 to 2.0, 0.05 to 2.0, 0.06 to 2.0, 0.07 to 2.0, 0.08 to 2.0, 0.09 to 2.0, or 0.1 to 2.0 mg / mL, or 0.02 to 1.5, 0.03 to 1.5, 0.04 to 1.5, 0.05 to 1.5, 0.06 to 1.5, 0.07 to 1.5, 0.08 to 1.5, or 0.09 to 1. 0.06-1.4, 0.07-1.4, 0.08-1.4, 0.09-1.4, 0.1-1.4 mg / mL, or 0.02-1, 0.03-1, 0.04-1, 0.05-1, 0.06-1, 0.07-1, 0.08-1, 0.09-1, 0.1-1 mg / mL.

[0096] The amphoteric polymer compound of the present invention exhibits excellent effects when contained in a solution or dispersion of a protein to be protected in order to inhibit protein aggregation or protect enzyme activity, even at a lower content than conventional compounds.

[0097] [Protection of Enzyme Activity] As described above, the amphoteric polymer compound of the present invention can exhibit an excellent inhibitory effect on protein aggregation against proteins to be protected. The inhibition of protein aggregation is effective in inhibiting protein denaturation, inhibiting protein deactivation, and realizing protection of protein function. The amphoteric polymer compound of the present invention actually inhibits enzyme deactivation and protects enzyme activity.

[0098] Therefore, the present invention also relates to a protein deactivation inhibitor, a protein function protector, an enzyme deactivation inhibitor, and an enzyme activity protector, each comprising the above-mentioned amphoteric polymer compound.The present invention also relates to a composition for inhibiting protein deactivation, a composition for protecting protein function, a composition for inhibiting enzyme deactivation, and a composition for protecting enzyme activity, each comprising the above-mentioned amphoteric polymer compound.The present invention also relates to the use of the above-mentioned amphoteric polymer compound for inhibiting protein deactivation, protecting protein function, inhibiting enzyme deactivation, and protecting enzyme activity.

[0099] Furthermore, the present invention also relates to a method for inhibiting protein inactivation, a method for protecting protein function, a method for inhibiting enzyme inactivation, and a method for protecting enzyme activity, each of which includes a step of adding the above-mentioned amphoteric polymer compound to a solution or dispersion of a protein to be protected, either prior to dissolving or dispersing the protein to be protected, or after dissolving or dispersing the protein to be protected.

[0100] Furthermore, the present invention also relates to methods for producing a protein solution or dispersion in which inactivation has been suppressed, a protein solution or dispersion in which function has been protected, an enzyme solution or dispersion in which inactivation has been suppressed, and an enzyme solution or dispersion in which activity has been protected, which are obtained by such methods for suppressing protein inactivation, protecting protein function, suppressing enzyme inactivation, and protecting enzyme activity.

[0101] In a preferred embodiment, the amphoteric polymer compound of the present invention can be contained in a solution or dispersion of an enzyme protein to be protected in order to suppress protein inactivation, protect protein function, suppress enzyme inactivation, and protect enzyme activity. The content of the amphoteric polymer compound of the present invention in the solution can be, for example, within the numerical range described above for the suppression of protein aggregation.

[0102] The present invention will be described in detail below with reference to examples. The present invention is not limited to the examples exemplified below. In the examples, "%" and "parts" indicate % by weight and parts by weight, respectively, unless otherwise specified.

[0103] Experimental Example 1 1. Polymer Synthesis Synthesis of Hydrophobic PLL-SA with Dodecyl Succinic Anhydride Added Thereto PLL-SA was obtained by mixing 1.27 g of succinic anhydride (SA, Nacalai Tesque) with 10 mL of ε-polylysine (PLL, 25% aqueous solution manufactured by JNC) and stirring for 2 hours at 50° C. Hydrophobized PLL-SA was synthesized by adding 0.1 g, 0.26 g, 0.42 g, or 0.53 g of dodecyl succinic anhydride (DDSA) to PLL-SA and stirring for 2 hours at 100° C., thereby synthesizing PLL-SA-DDSA 2%, PLL-SA-DDSA 5%, PLL-SA-DDSA 8%, and PLL-SA-DDSA 10%, respectively.

[0104] These compounds are hydrophobic PLL-SA obtained by adding dodecyl succinic anhydride to PLL-SA, and are therefore sometimes referred to as hydrophobic PLL-SA or hydrophobized PLL-SA. PLL-SA is sometimes written as PLLSA, and PLL-SA-DDSA is sometimes written as PLLSADDSA. Similarly, the abbreviations for the added compounds are sometimes written with a hyphen and sometimes without. The numbers immediately following the abbreviations represent the incorporation rate (%) of the compound represented by each abbreviation. For example, the numbers 2%, 5%, 8%, and 10% immediately following the word DDSA represent the incorporation rate of DDSA. That is, a compound in which the percentage (%) of amino groups reacted with DDSA among the amino groups contained as side chains in a PLL molecule is 2% is written as PLL-SA-DDSA2%. In the synthesis in the examples of this application, unless otherwise specified, the synthesis was carried out so that the introduction rate of SA was 65%. 1 This was performed by H-NMR. Percentage values ​​may be written as the value in parentheses, for example, PLL-SA 65% - DDSA 5% may be written as PLL-SA(65)-DDSA(5), or as PLLSA(65)DDSA(5), or as PLLSADDSA5%, or the % symbol may be omitted and written as PLLSADDSA5.

[0105] The ε-polylysine (PLL, 25% aqueous solution manufactured by JNC) used above had the following properties according to the published values ​​of the manufacturer: Number average molecular weight Mn: 4,090 Weight average molecular weight Mw: 4,700 Mw / Mn: 1.14

[0106] This ε-polylysine solution was close to monodisperse, and the degree of polymerization of the molecules was extremely uniform.

[0107] From the value of Mn, 4090 / 128=31.9 was obtained, and the average number of repeating units contained in the molecule was 32. That is, it was found that the average value of the degree of polymerization n of ε-polylysine was n=32.

[0108] As is well known, the relationship between the molecular weights Mw and Mn of a polymer and the standard deviation σ is σ = [Mn (Mw - Mn)] 1/2 Assuming that the molecular weight distribution is a normal distribution, the range of ±0.32σ from the average is 25%, the range of ±0.67σ from the average is 50%, the range of ±σ from the average is 68%, the range of ±1.28σ from the average is 80%, the range of ±1.6σ from the average is 90%, the range of ±2σ from the average is 95%, and the range of ±2.6σ from the average is 99%.

[0109] In this way, it was found that, with respect to the degree of polymerization n of ε polylysine, 80% of the molecules existed in the n range of 16 to 47, 68% of the molecules existed in the n range of 20 to 40, 50% of the molecules existed in the n range of 23 to 39, 25% of the molecules existed in the n range of 28 to 35, and 95% of the molecules existed in the n range of 7 to 56.

[0110] An illustration of the above synthesis flow is shown in Figures 1A and 1B.

[0111] The synthesized PLL-SA and PLL-SA-DDSA are 1 The structures of the molecules and the corresponding spectra are shown in Figures 2A to 2G. Figure 2A shows the structure of PLL-SA. Figure 2B shows the structure of D 2 Figure 2C shows the structure of PLL-SA-DDSA. Figure 2D shows the structure of PLL-SA-DDSA in D 2 Figure 2E shows the spectrum of PLL-SA(65)-DDSA(2) in O. 2 Figure 2F shows the spectrum of PLL-SA(65)-DDSA(5) in O. 2 Figure 2G shows the spectrum of PLL-SA(65)-DDSA(8) in O. 2 10. The spectrum of PLL-SA(65)-DDSA(10) in O.

[0112] [Synthesis of Hydrophobic PLLSA with Acid Anhydride Other Than Dodecylsuccinic Anhydride Added] In addition to the hydrophobic PLLSA with dodecylsuccinic anhydride added, hydrophobic PLLSAs were synthesized using octylsuccinic anhydride (OSA), decylsuccinic anhydride (DSA), 1,1-cyclopentanediacetic anhydride (CPDA), or phthalic anhydride (PA) instead of dodecylsuccinic anhydride as follows. In the synthesis of dodecyl succinic anhydride-added hydrophobic PLLSA, octyl succinic anhydride (OSA), decyl succinic anhydride (DSA), 1,1-cyclopentane diacetic anhydride (CPDA), and phthalic anhydride (PA) were used in place of dodecyl succinic anhydride in amounts of 0.33 g, 0.38 g, 0.26 g, and 0.23 g, respectively, and the mixture was stirred at 100°C for 2 hours to synthesize PLLSAOSA 8%, PLLSADSA 8%, PLLSACPDA 8%, and PLLSAPA 8%, respectively.

[0113]

[0114]

[0115]

[0116]

[0117] [2. Lysozyme Aggregation Inhibition Test] [Aggregation Inhibition Test for Heated Lysozyme (PLL-SA and PLL-SA-DDSA)] PLLSA, 2% PLLSADDSA, 5% PLLSADDSA, 8% PLLSADDSA, or 10% PLLSADDSA was added to lysozyme (0.2 mg / mL in PBS) at a concentration of 5 mg / mL, and the mixture was heated at 90°C for 1 hour, after which the absorbance at 500 nm was measured. The results are shown in Figure 3.

[0118] Figure 3 is a graph showing the change in absorbance when a lysozyme sample, a lysozyme sample with PLL-SA(65) (5 mg / mL) added, and a lysozyme sample with PLL-SA(65)-DDSA(8) (5 mg / mL) added were heated for up to 1 hour. The horizontal axis of Figure 3 represents heating time, and the vertical axis represents absorbance. As shown in Figure 3, in the absence of polymer, aggregation progressed with heating, resulting in an increase in absorbance, but in the polymer-added systems, there was almost no increase.

[0119] [Residual enzyme activity test for heated lysozyme (PLL-SA and PLL-SA-DDSA)] The polymer was added to lysozyme (0.2 mg / mL in PBS) at the specified concentration, and after heat treatment at 90°C for 30 minutes, the residual enzyme activity was measured. The results are shown in Figures 4A to 4D. In Figures 4A to 4D, the activity without heating was set to 100%.

[0120] Figure 4A shows the enzyme activity of lysozyme after treatment at 90°C in the presence of different polymers at 2.5 mg / mL, 5 mg / mL, 7.5 mg / mL, and 10 mg / mL, respectively. The enzyme activity is relative to the unheated value, which is set at 100%. Error bars indicate the standard deviation of the mean. ***: P < 0.0001; ns: no statistical difference.

[0121] The enzyme activity was investigated in a polymer-free system (PBS only) and when PLLSA, PLLSADDSA2, PLLSADDSA5, PLLSADDSA8, and PLLSADDSA10 were added at (A) 2.5 mg / mL, (B) 5 mg / mL, (c) 7.5 mg / mL, and (d) 10 mg / mL. PLLSADDSA8 and PLLSADDSA10 showed residual activity of 80% or more even at a low concentration of 2.5 mg / mL.

[0122] According to measurements by the present inventor's research group in Non-Patent Document 4, the protection of lysozyme by PSPB (polysulfobetaine) resulted in 90% of the residual enzyme activity of lysozyme when PSPB was added at 15%. In other words, compared to this PSPB, the PLL-SA-DDSA of the present invention exhibited the same or higher (90% or higher) residual enzyme activity when added at 7.5 mg / mL (0.75%), demonstrating that it exhibits a higher protective effect than PSPB even at a lower concentration.

[0123] [Residual Enzyme Activity Test for Heated Lysozyme (PLL-SA-OSA, PLL-SA-DSA, PLL-SA-CPDA, and PLL-SA-PA)] Figure 5 shows the residual enzyme activity of lysozyme when polymers prepared using hydrophobic acid anhydrides other than DDSA were added. The polymers used were PLLSAOSA8, PLLSADSA8, PLLSACPDA8, and PLLSAPA8. The polymers were added to lysozyme (0.2 mg / mL in PBS) at 10 mg / mL, and the mixture was heat-treated at 90°C for 30 minutes. The residual enzyme activity was measured after the addition. The vertical axis of the graph in Figure 5 represents the residual enzyme activity, which is expressed relative to the unheated value of 100%. Each polymer had an 8% hydrophobic group introduction rate. Each polymer exhibited a high residual activity of 80% or more at 10 mg / mL.

[0124] [3. LDH (lactate dehydrogenase) activity measurement] 200 μL of 63 mM NADH solution in PBS and 500 μL of 10 mM sodium pyruvate solution in PBS were mixed and diluted to 50 mL to prepare a substrate stock solution at pH 7.0. Next, a predetermined concentration of each polymer was mixed with a 20.7 mU / mL LDH solution (PBS) and incubated at 37°C for 1 hour. 5 μL of this solution was mixed with 195 μL of the substrate stock solution on a 96-well plate. The absorbance at 340 nm was measured for 20 minutes using a microplate reader (Tecan Infinite 200 PRO M Nano+). Enzyme activity was calculated from the rate of absorbance decrease. The results are shown in Figure 6.

[0125] The horizontal axis of the graph in Fig. 6 represents the type and concentration of each polymer, and the vertical axis of the graph in Fig. 6 represents the residual enzyme activity of LDH (lactate dehydrogenase), which is a relative value with the enzyme activity without heating taken as 100%.

[0126] As shown in FIG. 6, it was found that PLLSADDSA2, PLLSADDSA5, PLLSADDSA8, and PLLSADDSA10 all exhibited high residual activity at 0.5 to 1 mg / mL.

[0127] According to the results of previous research by the inventor's research group, even the most active micellar PSPB to date required a concentration of approximately 2 mg / mL to maintain 80% of its activity. In other words, PLL-SA-DDSA was found to exhibit equivalent protective activity at a concentration less than half that of the most active micellar PSPB to date.

[0128] [4. Residual Enzyme Activity Test for Heated Lysozyme (PLL-SA-DDSA)] A residual enzyme activity test for heated lysozyme was performed by varying the SA content of PLL-SA-DDSA. PLL-SA-DDSA with different SA contents was added at 5 mg / mL to lysozyme (0.2 mg / mL in PBS), and the mixture was heat-treated at 90°C for 30 minutes, after which the residual enzyme activity was measured. The results are shown in Figure 7. The vertical axis of the graph in Figure 7 represents the residual enzyme activity, which is a relative value with the unheated value taken as 100%.

[0129] The structure of PLL-SA-DDSA is as shown in Figure 1B. In Figure 1B, the compounds where x, y, and z have the following values ​​are the polymers used in Figure 7. PLLSA30DDSA8 (x:y:z=62:30:8) PLLSA50DDSA8 (x:y:z=42:50:8) PLLSA65DDSA8 (x:y:z=27:65:8) PLLSA70DDSA8 (x:y:z=22:70:8)

[0130] As shown in FIG. 7, when added at 5 mg / mL, PLLSA50DDSA8, PLLSA65DDSA8, and PLLSA70DDSA8 all showed excellent effects, but PLLSA70DDSA8 showed slightly higher activity.

[0131] The present invention provides a novel protein aggregation inhibitor, and is an industrially useful invention.

Claims

1. An amphoteric polymeric compound represented by the following formula I: Formula I: (In formula I, x, y, and z are integers each representing the number of repeating units present in a dispersed state in the molecule, where x is an integer ranging from 3 to 17, y is an integer ranging from 12 to 29, z is an integer ranging from 1 to 4, and L 1 is a divalent substituent represented by the following formula La or formula Lb: (However, in formula La, R21 and R22 are each independently any group selected from a hydrogen atom and a saturated or unsaturated C4 to C14 hydrocarbon group (excluding the case where R21 and R22 are both hydrogen atoms), or R21 and R22 together form a saturated or unsaturated five- or six-membered ring hydrocarbon group.) Formula Lb: (In formula Lb, R31, R32, R33 and R34 are each independently any group selected from a hydrogen atom and a saturated or unsaturated C4 to C14 hydrocarbon group (excluding the case where R31, R32, R33 and R34 are all simultaneously hydrogen atoms), or R31, R32, R33 and R34 are: R32 and R33 together form a saturated or unsaturated five- or six-membered hydrocarbon group, and R31 and R34 are hydrogen atoms, or R31, R32, R33 and R34 are: R31 and R32 together form a saturated or unsaturated five- or six-membered hydrocarbon group, and R33 and R34 are hydrogen atoms, or R31, R32, R33 and R34 are: R33 and R34 together form a saturated or unsaturated five- or six-membered hydrocarbon group, and R31 and R32 are hydrogen atoms. 1 The repeating unit containing L 1When the divalent substituent represented by formula La is a divalent substituent represented by formula La, the divalent substituents are contained in the molecule at an average value z of the number contained in the molecule, including the case where the end closer to R21 in formula La is bonded to the side closer to the PLL chain in formula I, and the case where the end closer to R22 in formula La is bonded to the side closer to the PLL chain in formula I, 1 The repeating unit containing L 1 is a divalent substituent represented by formula Lb, the divalent substituents represented by formula Lb are contained in the molecule at an average value z of the number contained in the molecule, including the case where the end closer to R31 in formula Lb is bonded to the side closer to the PLL chain in formula I, and the case where the end closer to R34 in formula Lb is bonded to the side closer to the PLL chain in formula I, 2 is -CH 2 -CH 2 - group, or -CH 2 -CH 2 -CH 2 A divalent substituent represented by the group L 2 The repeating unit containing L 2 is a divalent substituent represented by -CH 2 -CH 2 - is a divalent substituent represented by a -CH 2 -CH 2 -CH 2 The divalent substituents represented by the - group are included, and the average number of divalent substituents represented by the - group is y.

2. ε-poly-L-lysine is reacted with succinic anhydride and a compound represented by the following formula II: (In the formula II, L 1 The amphoteric polymer compound according to claim 1, which is obtained by reacting 3. The amphoteric polymeric compound according to claim 1, which is an amphoteric polymeric compound represented by the following formula Ia: Formula Ia: (wherein in formula Ia, x, y, and z have the numerical values ​​as described for formula I in claim 1; L 1 is a divalent substituent as described for formula I in claim 1.

4. The amphoteric polymer compound according to claim 1, wherein the value of x+y+z is an integer in the range of 23 to 39.

5. The saturated or unsaturated C4 to C14 hydrocarbon group is -C n H 2n+1 group (wherein n is an integer of 4 to 14), -C n H 2n-1 group (wherein n is an integer of 4 to 14), -C n H 2n-3 group (wherein n is an integer of 4 to 14), -C n H 2n-5 2. The amphoteric polymer compound according to claim 1, wherein n is any group selected from the group consisting of aryl, aryl, aryl and aryl groups (wherein n is an integer of 4 to 14).

6. A protein aggregation inhibitor comprising the amphoteric polymer compound according to any one of claims 1 to 5.

7. A composition for inhibiting protein aggregation, comprising the amphoteric polymer compound according to any one of claims 1 to 5.

8. An agent for protecting enzyme activity, comprising the amphoteric polymer compound according to any one of claims 1 to 5.

9. A composition for protecting enzyme activity, comprising the amphoteric polymer compound according to any one of claims 1 to 5.

10. Use of the amphoteric polymer compound according to any one of claims 1 to 5 for inhibiting protein aggregation.

11. Use of the amphoteric polymer compound according to any one of claims 1 to 5 for protecting enzyme activity.

12. A method for inhibiting protein aggregation, comprising a step of adding the amphoteric polymer compound according to any one of claims 1 to 5 to a solution or dispersion of a protein to be protected prior to dissolving or dispersing the protein to be protected, or after dissolving or dispersing the protein to be protected.

13. A method for producing a protein solution or dispersion in which aggregation is inhibited by the method for inhibiting protein aggregation described in claim 12.

14. A method for protecting the enzymatic activity of an enzyme protein, comprising a step of adding an amphoteric polymer compound described in any one of claims 1 to 5 to a solution or dispersion of the enzyme protein to be protected prior to dissolving or dispersing the enzyme protein to be protected, or after dissolving or dispersing the enzyme protein to be protected.

15. A method for producing an enzyme protein solution or dispersion whose enzymatic activity is protected by the method for protecting the enzymatic activity of an enzyme protein according to claim 14.

Citation Information

Patent Citations

  • Cell freeze damage preventing liquid for medical use

    JP2011030557A

  • Methods for inhibiting polypeptide aggregation

    JP2019147787A

  • Cross-linked collagen

    JP2023001803A

  • Protein aggregation inhibitor

    WO2016181975A1

  • Vitrification stabilizer for animal cell cryopreservation fluid

    WO2016195121A1